Search research articles
Contact Us
Filters
Showing results (311-320 of 357) with videos related to
Page
of 36
Sort By:
Urologic Oncology
|
September 28, 2021
Somatic mutations as preoperative predictors of metastases in patients with localized clear cell renal cell carcinoma - An exploratory analysis
Roy Mano, Cihan Duzgol, Maz Ganat, et al.
Medrxiv : the Preprint Server for Health Sciences
|
January 23, 2024
Effect of testosterone therapy on breast tissue composition and mammographic breast density in trans masculine individuals
Yujing J Heng, Gabrielle M Baker, Valerie J Fein-Zachary, et al.
Journal of Proteome Research
|
May 30, 2012
Interlaboratory reproducibility of selective reaction monitoring assays using multiple upfront analyte enrichment strategies
Amol Prakash, Taha Rezai, Bryan Krastins, et al.
Lancet (London, England)
|
February 12, 2023
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial
Robert J Motzer, Paul Russo, Viktor Grünwald, et al.
European Urology
|
February 20, 2022
Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy
Maria I Carlo, Kyrollis Attalla, Yousef Mazaheri, et al.
European Urology Oncology
|
November 27, 2025
Pathologic Response to Immunotherapy Is Associated with Survival in Patients Undergoing Delayed Nephrectomy for Metastatic Renal Cell Carcinoma
Yash S Khandwala, Stephen W Reese, Burcin A Ucpinar, et al.
European Urology Focus
|
March 15, 2022
Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas
Angela Yoo, Cerise Tang, Mark Zucker, et al.
Targeted Oncology
|
September 2, 2023
Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial
Robert J Motzer, Paul Russo, Viktor Grünwald, et al.
Cancer Cell
|
January 15, 2016
An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma
A Ari Hakimi, Ed Reznik, Chung-Han Lee, et al.
Cell Metabolism
|
July 6, 2023
Immunometabolic coevolution defines unique microenvironmental niches in ccRCC
Cerise Tang, Amy X Xie, Eric Minwei Liu, et al.
Page
of 36
Search research articles
Search
Showing results (311-320 of 357) with videos related to
Sort By:
Page
of 36
Urologic Oncology
|
September 28, 2021
Somatic mutations as preoperative predictors of metastases in patients with localized clear cell renal cell carcinoma - An exploratory analysis
Roy Mano, Cihan Duzgol, Maz Ganat, et al.
Medrxiv : the Preprint Server for Health Sciences
|
January 23, 2024
Effect of testosterone therapy on breast tissue composition and mammographic breast density in trans masculine individuals
Yujing J Heng, Gabrielle M Baker, Valerie J Fein-Zachary, et al.
Journal of Proteome Research
|
May 30, 2012
Interlaboratory reproducibility of selective reaction monitoring assays using multiple upfront analyte enrichment strategies
Amol Prakash, Taha Rezai, Bryan Krastins, et al.
Lancet (London, England)
|
February 12, 2023
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial
Robert J Motzer, Paul Russo, Viktor Grünwald, et al.
European Urology
|
February 20, 2022
Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy
Maria I Carlo, Kyrollis Attalla, Yousef Mazaheri, et al.
European Urology Oncology
|
November 27, 2025
Pathologic Response to Immunotherapy Is Associated with Survival in Patients Undergoing Delayed Nephrectomy for Metastatic Renal Cell Carcinoma
Yash S Khandwala, Stephen W Reese, Burcin A Ucpinar, et al.
European Urology Focus
|
March 15, 2022
Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas
Angela Yoo, Cerise Tang, Mark Zucker, et al.
Targeted Oncology
|
September 2, 2023
Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial
Robert J Motzer, Paul Russo, Viktor Grünwald, et al.
Cancer Cell
|
January 15, 2016
An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma
A Ari Hakimi, Ed Reznik, Chung-Han Lee, et al.
Cell Metabolism
|
July 6, 2023
Immunometabolic coevolution defines unique microenvironmental niches in ccRCC
Cerise Tang, Amy X Xie, Eric Minwei Liu, et al.
Page
of 36